PP
CALA

PDT Partners’s Calithera Biosciences, Inc CALA Stock Holding History

PDT Partners’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,191
Closed -$82K – 893
2020
Q3 		$82K Buy
+1,191
New +$104K 0.01% 690
2017
Q3 		– Sell
-935
Closed -$278K – 587
2017
Q2 		$278K Buy
+935
New +$250K 0.01% 461

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PDT Partners's CALA Position: Q4 2020 in Review

PDT Partners sold out of Calithera Biosciences, Inc (CALA) in Q4 2020, closing a stake of 1,191 shares — an estimated $82K sold.

PDT Partners first reported a position in CALA in Q2 2017 and held it in 2 quarters. The position peaked at $278K in Q2 2017. 105 funds tracked by Wall St. Rank hold CALA as of Q4 2020.

  • PDT Partners reported no remaining Calithera Biosciences, Inc position as of Q4 2020 after selling out during the quarter.
  • PDT Partners sold 1,191 Calithera Biosciences, Inc shares in Q4 2020, an estimated $82K.
  • PDT Partners first reported a position in Calithera Biosciences, Inc in Q2 2017 and held it in 2 quarters.
  • PDT Partners's Calithera Biosciences, Inc position peaked at $278K in Q2 2017.
  • 105 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q4 2020.

Based on PDT Partners's 13F filing for Q4 2020, filed 16 Feb 2021.